论文部分内容阅读
目的 提高人脑胶质瘤过继免疫治疗的效果 ,探索治疗脑胶质瘤的新途径。方法 用人参皂甙 (GS)、抗CD3单抗 (CD3 )和 IL-2共同诱导人外周血单个核细胞 (PBMC) ,诱导、扩增新型抗胶质瘤效应细胞 GS-CD3 AK细胞 ,并与 CD3 AK细胞在某些生物学方面进行了比较。结果 两组效应细胞增殖曲线均于第 6天达高峰 ,峰值可见 GS-CD3 AK细胞 >CD3 AK细胞 (P <0 .0 5 ) ;GS-CD3 AK细胞扩增倍数明显高于 CD3 AK细胞 (P <0 .0 5 ) ;两组效应细胞于培养的第 6天所测得的杀伤恶性脑胶质瘤细胞 BT3 2 5活性可见 GS-CD3 AK细胞 >CD3 AK细胞 (P <0 .0 5 )。结论 GS、CD3和 IL-2具有协同增强作用 ,使 GS-CD3 AK细胞成为较 CD3 AK细胞增殖能力、杀伤活性更强的免疫效应细胞 ,且 IL-2用量减少 ,为胶质瘤的过继免疫治疗打下了理论基础。
Objective To improve the effect of adoptive immunotherapy in human glioma and explore new ways to treat glioma. Methods Human peripheral blood mononuclear cells (PBMCs) were induced with ginsenoside (GS), anti-CD3 monoclonal antibody (CD3) and IL-2 to induce and amplify a novel anti-glioma effector cell line GS- CD3 AK cells are compared in some biological aspects. Results The proliferative curve of effector cells in both groups reached the peak on the 6th day. GS-CD3 AK cells> CD3 AK cells (P <0.05) peaked at the peak, and the multiplication of GS-CD3 AK cells was significantly higher than that of CD3 AK cells P <0. 05). The activity of BT3 2 5 in malignant glioma cells measured on the 6th day of culture in both groups showed that GS-CD3 AK cells> CD3 AK cells (P <0.05 ). Conclusions GS, CD3 and IL-2 have a synergistic enhancing effect, making GS-CD3 AK cells an immunocompetent cell with stronger proliferation and killing activity than CD3 AK cells, and the dosage of IL-2 is reduced, so as to make the glioma adoptive immunity Treatment laid the theoretical foundation.